Semaglutide, the weight management drug sold as Ozempic and Wegovy, may reduce the risk of Alzheimer's disease by 40% to 70% ...

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

In the present study, researchers investigated the prescription trends of GLP-1RAs (albiglutide, dulaglutide, semaglutide, ...

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's ( NVO) semaglutide and Eli Lilly's ( LLY) tirzepatide could also be effective in tackling Alzheimer's disease.

Semaglutide, the active ingredient in Ozempic and Wegovy, may also help lower the risk of developing Alzheimer’s disease in people living with type 2 diabetes.

A total of 3 trials of GLP-1 receptor agonists (albiglutide, efpeglenatide, and semaglutide) with 1743/17,072 (10.2%) patients receiving an SGLT2 inhibitor at baseline were included. The available ...

GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

This is because GLP-1 based weight loss drugs, liraglutide, albiglutide, and dulaglutide, were first approved by the FDA in ...

Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted ...

Several other formulations with unique structures and properties are being investigated in ongoing clinical trials including albiglutide, semaglutide, dulaglutide and ITCA650. Published and ...

and other GLP-1RAs (albiglutide, dulaglutide, exenatide, liraglutide, and lixisenatide). Their methodology involved using target trial emulation, a type of study that aims to mimic a randomized ...